At the time the study was performed, we unfortunately did not record the number of patients screened for eligibility or excluded before randomization for our vascular function studies. Generally, around 30% of patients approached agreed to participate in the invasive venous plethysmography studies. Three patients were not included in the final analysis. One patient complained of chest pain when he arrived for his second visit (after completing the omega-3 intervention arm) and was admitted with suspected unstable angina. He underwent coronary intervention and made an uncomplicated recovery. An adverse event was logged and the patient withdrawn from the study. The event was reviewed by the Chief Investigator and Independent Advisor and felt unlikely to be related to the omega-3 supplements. Two patients withdrew from the study because they found returning for subsequent visits inconvenient.